Granahan Investment Management LLC Trims Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Granahan Investment Management LLC cut its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 23.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 115,687 shares of the biopharmaceutical company's stock after selling 35,098 shares during the quarter. Granahan Investment Management LLC owned 0.20% of Agios Pharmaceuticals worth $3,801,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Summit Investment Advisors Inc. lifted its position in Agios Pharmaceuticals by 7.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock valued at $194,000 after purchasing an additional 394 shares during the last quarter. Federated Hermes Inc. lifted its position in Agios Pharmaceuticals by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock valued at $450,000 after purchasing an additional 582 shares during the last quarter. KBC Group NV lifted its holdings in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Agios Pharmaceuticals by 1.2% in the 4th quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock worth $2,021,000 after acquiring an additional 708 shares during the last quarter. Finally, Atria Investments Inc lifted its holdings in shares of Agios Pharmaceuticals by 6.9% in the 4th quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock worth $373,000 after acquiring an additional 737 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AGIO. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective for the company. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Scotiabank lowered their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $56.00.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO traded down $0.71 during midday trading on Wednesday, reaching $28.03. 610,838 shares of the stock traded hands, compared to its average volume of 696,302. The company has a fifty day moving average of $29.03 and a 200 day moving average of $37.00. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58. The stock has a market capitalization of $1.62 billion, a P/E ratio of 2.47 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. The company had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. This represents a 4.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.